ArticlePharmacological research2010
P2Y(13) receptor is responsible for ADP-mediated degranulation in RBL-2H3 rat mast cells.
Article in Pharmacological research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Characterization of Potency of the P2Y13 Receptor Agonists: A Meta-Analysis.International journal of molecular sciences · 2021Pooled it
- Microglial purinergic signaling in Alzheimer's disease.Purinergic signalling · 2025Review
- Pharmacological interaction and immune response of purinergic receptors in therapeutic modulation.Purinergic signalling · 2024Review
- Pharmacological characterization of P2Y receptor subtypes - an update.Purinergic signalling · 2024Review
- P2X7 Receptor-Induced Human Mast Cell Degranulation Is Enhanced by Interleukin 33.International journal of molecular sciences · 2024Article
- Enteric glia promote visceral hypersensitivity during inflammation through intercellular signaling with gut nociceptors.Science signaling · 2023Article
- Activation of hypermethylated P2RY1 mitigates gastric cancer by promoting apoptosis and inhibiting proliferation.Open life sciences · 2023Article
- Inhibiting the P2YPurinergic signalling · 2022Article
- Physiologic roles of P2 receptors in leukocytes.Journal of leukocyte biology · 2022Review
- Synergistic Cytokine Production by ATP and PGECells · 2022Article
- Decoding the Mechanism behind the Pathogenesis of the Focal Segmental Glomerulosclerosis.Computational and mathematical methods in medicine · 2022Article
- Activation of spinal dorsal horn P2YJournal of pain research · 2018Article
- Gene-based analysis of regulatory variants identifies 4 putative novel asthma risk genes related to nucleotide synthesis and signaling.The Journal of allergy and clinical immunology · 2017Article
- Purinergic Signaling in Mast Cell Degranulation and Asthma.Frontiers in pharmacology · 2017Review
- Nucleoside 5'-O-monophosphorothioates as modulators of the P2Y14 receptor and mast cell degranulation.Oncotarget · 2016Article
- Neuroprotection Mediated by P2Y13 Nucleotide Receptors in Neurons.Computational and structural biotechnology journal · 2015Review
- The enteric nervous system of P2Y13 receptor null mice is resistant against high-fat-diet- and palmitic-acid-induced neuronal loss.Purinergic signalling · 2014Article
- Role of the ubiquitin-proteasome system in the regulation of P2Y13 receptor expression: impact on hepatic HDL uptake.Cellular and molecular life sciences : CMLS · 2014Article
- Purinergic signaling in inflammatory cells: P2 receptor expression, functional effects, and modulation of inflammatory responses.Purinergic signalling · 2013Review
- The role of P2Y(14) and other P2Y receptors in degranulation of human LAD2 mast cells.Purinergic signalling · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Extracellular ADP is known to play many important physiological roles. In this study, we identified the P2Y(13) receptor in a rat mast cell line (RBL-2H3) and explored the functional role of ADP, its endogenous agonist. ADP induced both intracellular calcium mobilization and release of hexosaminidase (Hex). In an assay of intracellular calcium, ADP was 100-fold less potent than and equally efficacious as the P2Y(1) receptor-selective agonist MRS2365. However, ADP was more potent and efficacious than MRS2365 in inducing Hex release and in enhancing antigen-induced Hex release. ADP-induced intracellular calcium mobilization was blocked by phospholipase C inhibitor U73122 and by P2Y(1) receptor-selective antagonist MRS2500, but not by pertussis toxin (PTX), suggesting a mechanism mediated by the G(q)-coupled P2Y(1) receptor, but not P2Y(13) (G(i)-coupled) or P2X receptors. ADP-induced Hex release was blocked by PTX and a selective P2Y(13) receptor antagonist MRS2211, but not by MRS2500 or P2Y(1) receptor-specific siRNA, suggesting a G(i)-coupled P2Y(13) receptor-related mechanism. Measurement of gene expression confirmed high expression of both P2Y(1) and P2Y(13) receptors (in comparison to a previously reported P2Y(14) receptor) in RBL-2H3 cells. Thus, we demonstrated that ADP-mediated intracellular calcium mobilization and Hex release in RBL-2H3 cells are via P2Y(1) and P2Y(13) receptors, respectively. Selective antagonists of the P2Y(13) receptor might be novel therapeutic agents for various allergic conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.